Navigation Links
Significantly Higher Percentage of Hetastarch Recipients Underwent a Surgical Procedure Than Those Receiving Albumin/Plasma Protein Fraction
Date:9/17/2009

MALVERN, Pa., Sept. 17 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that for the January - May 2009 time period, a significantly higher percentage of hetastarch recipients (75%) underwent a surgical procedure when compared to those receiving albumin/plasma protein fraction (51%). Hetastarch, albumin and plasma protein fraction are plasma expanders that are mainly used in hospital patients to replace fluid in cases of severe shock, as may occur with blood or fluid loss during surgery.

The newly released U.S. edition of the Plasma Expander Hospital Inpatient Profile Study also finds that albumin 25% is most often administered to patients with liver disease and hypotension/shock due to infection or surgical blood loss. Similarly, albumin and plasma protein fraction 5% are most often administered to patients with hypotension/shock from surgical blood loss, cardiogenic hypotension/shock and cardiopulmonary bypass procedures.

AMR's new Plasma Expander Hospital Inpatient Profile Study clinically characterizes U.S. hospital inpatient recipients of plasma expanders such as albumin, plasma protein fraction and hetastarch to identify relative usage patterns by indication, patient age and sex, prescribing physician specialty, dosing and primary method of payment.

"The new Plasma Expander Hospital Inpatient Profile Study is a nice complementary study to our Plasma Expander Hospital Purchasing Audit," stated Mary Walker, R.Ph., MBA, therapeutics principal director at AMR. "While the Purchasing Audit enables pharmaceutical companies to monitor the market size, market potential or market influences of plasma expanders, the Inpatient Profile Study allows these same companies to monitor plasma expander users and prescribers."

Why Pharmaceutical Companies Need this Information

The Plasma Expander Hospital Inpatient Profile Study enables pharmaceutical companies to monitor patient shares, prescribing physician specialty, dosing and payment method of plasma expander use in the hospital setting.

About AMR

AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Gisselle Morales                             Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    gmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Arlington Medical Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Data Show ChloraPrep(R) Significantly More Effective Than DuraPrep(TM) and Povidone-Iodine in Eliminating Bacteria From Skin Prior to Shoulder Surgery
2. HealthWarehouse.com, Inc. Announces Second Quarter Financial Results; Revenues Increase Significantly Over Second Quarter 2008
3. Iterative reconstruction technique significantly reduces patient radiation dose during CT scans
4. Cord Blood America Says Balance Sheet Significantly Strengthened in 2009
5. Heavy drinkers face significantly increased cancer risk
6. Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported
7. Hospital for Special Surgery is Only New York Hospital with Significantly Lower Surgical Site Infection Rate for Hip Replacement Compared to State Average
8. The Latin American Digital Radiography Market to Grow Significantly due to the Need to Improve Digital Adoption, Observes Frost & Sullivan
9. Published Study Shows VNUS ClosureFAST™ System Significantly Superior to Laser for Varicose Vein Treatment
10. Botox injections can significantly improve quality of life for people with overactive bladders
11. VIVUS Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... The Magic ... “Consumer’s Choice” Award, for favorite sex toy. Created in collaboration with website Kinkly.com, ... to be consumer voted. The Magic Wand Rechargeable won in stiff competition from ...
(Date:7/24/2017)... VA (PRWEB) , ... July 24, 2017 , ... ... Managers, **Presented by FDAnews and MSceppa Consulting **, Aug. 22-23, 2017 – Arlington, ... on Friday, July 28. , Increased FDA scrutiny and growing demands to track ...
(Date:7/24/2017)... ... July 24, 2017 , ... Advanced Dermatology, ... Bellmore, New York, (516) 784-5858. The office opened earlier this summer and is ... Friedman and Fruma Leah Wiederman. , Advanced Dermatology, P.C. founder and medical ...
(Date:7/24/2017)... ... ... “A Short Walk to the Mailbox”: a remarkable memoir of an unconventional courtship. ... Ed Clark is a church music director and choral conductor. He has ... worship leader for over fifty years. He has a master’s degree in church ...
(Date:7/23/2017)... ... 2017 , ... Three experts will be interviewed on Facebook ... & Exhibition, to be held in Denver, CO on July 30-August 3, 2017. ... visit the AAPM Facebook page to watch three speakers present their information and ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... to resolve pending patent litigation in the U.S. District Court ... regarding the Cialis ® (tadalafil) unit dose patent. This ... As part of the agreement, Cialis exclusivity is now expected ... "The unit dose patent for Cialis is valid and ...
(Date:7/11/2017)... 11, 2017  Sysmex America, Inc., a leading ... equipment as well as middleware information systems technology, ... make quality assurance easier and more risk free ... known for the innovation that it delivers to ... quality assurance processes to a new level with ...
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
Breaking Medicine Technology: